SCHEMBL29911307

SCHEMBL29911307

[2H]C1C=Cc2ccccc2N1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 9/20 0.34
HTR1A P08908 4/20 0.34
DRD2 P14416 4/20 0.34
HTR2A P28223 4/20 0.34
HTR6 P50406 3/20 0.34
SLC6A4 P31645 3/20 0.34
HRH1 P35367 3/20 0.34
HTR7 P34969 1/20 0.34
P2RX1 P51575 5/20 0.33
P2RX3 P56373 5/20 0.33
MAPK1 P28482 2/20 0.33
P2RX7 Q99572 2/20 0.33
LMNA P02545 2/20 0.33
MTNR1A P48039 2/20 0.33
MTNR1B P49286 2/20 0.33
TSHR P16473 1/20 0.33
SCN4A P35499 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN9A Q15858 1/20 0.33
CHRM2 P08172 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29434173 0.81 P2RX4 (0.37) P2RX4HTR1ADRD2HTR2AHTR6
SCHEMBL1198914 0.81 P2RX4 (0.37) P2RX4HTR1ADRD2HTR2AHTR6
Hydrochloric Acid SCHEMBL29035745 0.79 MEN1 (0.37) P2RX4HTR1ADRD2HTR2AHTR6
Iodide SCHEMBL27879086 0.79 P2RX4 (0.36) P2RX4HTR1ADRD2HTR2AHTR6
Iodide SCHEMBL7101346 0.79 P2RX4 (0.36) P2RX4HTR1ADRD2HTR2AHTR6
Iodide SCHEMBL30253496 0.79 P2RX4 (0.36) P2RX4HTR1ADRD2HTR2AHTR6
Iodide SCHEMBL27895829 0.78 MAPT (0.36) P2RX4HTR1ADRD2HTR2AHTR6
SCHEMBL12013901 0.76 HTR1A (0.36) P2RX4HTR1ADRD2HTR2AHTR6
SCHEMBL27890223 0.74 P2RX4 (0.33) P2RX4HTR1ADRD2HTR2AHTR6
SCHEMBL28221845 0.74 P2RX4 (0.33) P2RX4HTR1ADRD2HTR2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2024-04-09 US disclosed
US-20220267339-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2022-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267339-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 P2RX4 4604/4885HTR1A 4590/4885DRD2 4790/4885
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 P2RX4 4604/4885HTR1A 4590/4885DRD2 4790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.